Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC
Schaefer-Schuler A, Blickle A, Ganz S, Petto S, Burgard C, Speicher T, Bastian MB, Maus S, Bartholomä M, Ezziddin S, Rosar F (2026)
Publication Type: Journal article
Publication year: 2026
Journal
DOI: 10.1007/s00259-026-08171-z
Abstract
Purpose: Terbium-161 (161Tb) has emerged as a promising radionuclide for radioligand therapy (RLT) due to its emission of Auger and conversion electrons, which may support therapeutic efficacy through increased local energy deposition. Despite growing research efforts aimed at the clinical potential of 161Tb, dosimetric data, particularly for tumor lesions, remain scarce. To address this gap, we assessed tumor and organ dosimetry in mCRPC patients treated with [161Tb]Tb-PSMA-617. Methods: The study involved n = 15 patients with metastasized castration-resistant prostate cancer (mCRPC) participating in a registry (NCT04833517) and receiving [161Tb]Tb-PSMA-617. All patients received a median of 2 (range: 1–3) cycles with mean administered activity of 6.0 ± 1.3 GBq and mean cumulative activity of 12.3 ± 4.6 GBq [161Tb]Tb-PSMA-617. Hybrid dosimetry of organs at risk, including the salivary glands, the kidneys, the liver, and tumor lesions was performed analyzing whole-body planar and SPECT/CT images. Absorbed doses were estimated using OLINDA/EXM for 161Tb. Tumor-to-organ ratios (TR) of mean tumor-absorbed doses over relevant organs at risk were calculated. Results: Mean absorbed dose to kidneys, parotid glands, submandibular glands and liver was 0.70 ± 0.41 Gy/GBq, 0.40 ± 0.20 Gy/GBq, 0.36 ± 0.14 Gy/GBq and 0.13 ± 0.08 Gy/GBq, respectively. Tumor kinetics in 43 lesions demonstrated stable activity over time (mean half-life of all lesions: 44.07 h ± 15.88 h) delivering a mean overall absorbed tumor dose of 5.95 ± 3.60 Gy/GBq, the resulting TR over kidney and parotid gland were 10.55 ± 8.32 and 16.15 ± 11.85, respectively. Conclusion: [161Tb]Tb-PSMA-617 delivers high tumor-absorbed doses with tolerable doses to relevant organs at risk, translating into favorable tumor-to-normal-organ ratios. Dosimetry results confirm 161Tb as a promising radionuclide for PSMA-targeted radioligand therapy in mCRPC.
Involved external institutions
Germany (DE)How to cite
APA:
Schaefer-Schuler, A., Blickle, A., Ganz, S., Petto, S., Burgard, C., Speicher, T.,... Rosar, F. (2026). Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08171-z
MLA:
Schaefer-Schuler, Andrea, et al. "Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC." European Journal of Nuclear Medicine and Molecular Imaging (2026).
BibTeX: Download